T0	Outcomes 841 872	pooled efficacy and safety data
T1	Outcomes 1022 1050	Median overall survival (OS)
T2	Outcomes 1319 1321	OS
T3	Outcomes 1443 1551	Ipilimumab-induced adverse events and immune-related adverse events (skin, gastrointestinal, hepatic, other)